Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Capital Expenditures (2020 - 2025)

Lyell Immunopharma's Capital Expenditures history spans 6 years, with the latest figure at -$414000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 22.49% year-over-year to -$414000.0; the TTM value through Sep 2025 reached $121000.0, up 104.64%, while the annual FY2024 figure was $144000.0, 396.55% up from the prior year.
  • Capital Expenditures for Q3 2025 was -$414000.0 at Lyell Immunopharma, down from $259000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $48.7 million in Q3 2021 and bottomed at -$13.3 million in Q3 2022.
  • The 5-year median for Capital Expenditures is $220000.0 (2024), against an average of $4.7 million.
  • The largest annual shift saw Capital Expenditures surged 986.09% in 2021 before it crashed 273.33% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $10.3 million in 2021, then surged by 101.72% to $20.7 million in 2022, then crashed by 112.71% to -$2.6 million in 2023, then soared by 104.6% to $121000.0 in 2024, then crashed by 442.15% to -$414000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Capital Expenditures are -$414000.0 (Q3 2025), $259000.0 (Q2 2025), and $155000.0 (Q1 2025).